HomeIMAGING

Combining best-in-class AI-powered Technologies for Musculoskeletal (MSK) Imaging Workflows – ImageBiopsy Lab and Radiobotics sign Collaboration Agreement

Musculoskeletal (MSK) Imaging Workflows

ImageBiopsy Lab (Vienna, Austria) and Radiobotics (Copenhagen, Denmark) have teamed up to advance the use of Artificial-Intelligence (AI) supported disease diagnostics for musculoskeletal (MSK), orthopaedic, and trauma use-cases in the DACH region.

Globally, musculoskeletal conditions affect a larger population than circulatory or respiratory disorders. Despite this, diagnostic methods often remain rooted in outdated practices, relying on manual interpretation of X-rays and MRI images. These subjective and time-intensive techniques lack standardisation and depend on practitioner expertise.

Despite a growing number of MSK-specific solutions, users lack a holistic answer for diverse diagnostic needs. With their collaboration ImageBiopsy Lab and Radiobotics (both with MDR and FDA clearances) will merge their expertise and provide a single, comprehensive solution for MSK imaging, encompassing measurement, scoring, and fracture detection workflow.

Dr. Richard Ljuhar, CEO and Co-Founder of ImageBiopsy Lab, explains, “Before even considering the use of AI, it’s crucial to grasp physicians’ diagnostic workflow and needs. For this purpose we’ve closely collaborated with leading MSK radiologists, orthopaedics, and traumatologists over the past years. We’re committed to revolutionizing the entire MSK diagnostic value chain for practitioners, patients, and healthcare systems.

We see Radiobotics as the logical partner to offer best in class solutions for MSK conditions diagnostics, from measurements and scoring to fracture detection. Our collaboration marks the next AI-powered workflow integration phase.

Mads Jarner, CEO and Co-founder of Radiobotics, notes, “As MSK AI solutions gain traction in clinical workflows, providing clinics with integrated and comprehensive options becomes vital. We’re thrilled to collaborate with ImageBiopsy Lab to facilitate access to our market-leading solutions. Leveraging ImageBiopsy Lab’s expertise and network in German-speaking regions, we’re excited to introduce our RBfracture™ fracture detection solution in this area initially, with potential expansion to other regions.

SourceImageBiopsy Lab
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism

“The completion of the APEX-AV Study represents an important milestone in the catheter-directed therapies CDT space for the treatment of pulmonary embolism. I sincerely thank all the investigators for their commitment and dedication,” said William Brent Keeling, MD, Associate Professor of Surgery, Department of Surgery, at the Emory University School of Medicine, and Immediate Past President, The PERT Consortium™.

Cordance Medical Announces Agreement with Stanford Medicine’s Airan and Williams Labs for Precision Neuropsychiatry with Ultrasonic Drug Uncaging Technology

The combined expertise of Cordance Medical and the Airan and Williams Labs will see NeuroAccess utilized to deliver a novel application of drug-loaded nanoparticles, providing targeted drug delivery to the brain.

Medixine Continues Growth in the U.S.

Medixine prepares for 2024 with two key senior hires, VP of Operations in the U.S. and VP of Engineering in Finland. The appointments will enhance support and service to the company’s U.S.-based partners, including leading respiratory homecare provider Lincare and a major medical device manufacturer. In addition, the new hires will enable streamlined design, testing, and deployment of new product features for more patient-centric, cost and time-effective treatment of chronic conditions.

Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study

Innovent Biologics and Synaffix: Under the terms of the expanded agreement, Innovent will be responsible for the research, development, manufacturing and commercialization of new ADC candidates. Synaffix is eligible to receive an upfront payment plus potentialmilestone payments and royalties on commercial sales for each licensed target.

Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society 2023 Annual Meeting

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.

Medical Device News Magazine

Editorial Contact: mdnewsmagazine@infomeddnews.com

Medical Device News Magazine can help promote your medical devices, technologies, products or services. Advertising Contact: advmdn@infomeddnews.com

Telephone

© Copyright 2022 Medical Device News Magazine, is a division of PTM Healthcare Marketing, Inc

By using this website you agree to accept Medical Device News Magazine Privacy Policy